William Blair Issues Positive Outlook for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities research analysts at William Blair raised their Q2 2026 earnings per share estimates for Apellis Pharmaceuticals in a report issued on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of $0.20 for the quarter, up from their previous estimate of $0.18. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q3 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.47 EPS and FY2026 earnings at $1.01 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. The company’s revenue was up 45.2% on a year-over-year basis.

Other research analysts also recently issued reports about the company. The Goldman Sachs Group cut their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Royal Bank of Canada dropped their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research note on Monday, March 3rd. Wedbush dropped their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Scotiabank raised their price target on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.59.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $23.00 on Thursday. The stock’s fifty day moving average price is $26.58 and its 200-day moving average price is $29.21. Apellis Pharmaceuticals has a 12 month low of $21.70 and a 12 month high of $58.12. The firm has a market cap of $2.89 billion, a P/E ratio of -11.33 and a beta of 0.92. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of APLS. EverSource Wealth Advisors LLC increased its holdings in shares of Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after purchasing an additional 758 shares during the last quarter. Signaturefd LLC grew its holdings in Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Apellis Pharmaceuticals in the 4th quarter worth $83,000. US Bancorp DE raised its holdings in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after acquiring an additional 1,327 shares during the period. Finally, Covestor Ltd boosted its position in shares of Apellis Pharmaceuticals by 1,819.2% during the 4th quarter. Covestor Ltd now owns 3,992 shares of the company’s stock valued at $127,000 after acquiring an additional 3,784 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.96. Following the sale, the insider now owns 55,560 shares of the company’s stock, valued at $1,878,483.60. The trade was a 4.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the sale, the chief accounting officer now owns 48,138 shares of the company’s stock, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,054 shares of company stock worth $1,952,719 over the last quarter. 6.80% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).